Semaglutide — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Semaglutide

Also known as: Ozempic, Wegovy, Rybelsus, GLP-1 analogue, GLP-1 receptor agonist

Glucagon-like peptide-1 receptor agonist (GLP-1 RA)

Research chemicalLast updated: October 31, 2026Based on 31 peer-reviewed studies

What it is

Semaglutide is the active ingredient in Ozempic and Wegovy — prescribed for type 2 diabetes and weight loss. It works by curbing appetite and controlling blood sugar. Prescription only; also being studied for heart, kidney, and liver conditions.

The scientific side

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that binds and activates the GLP-1 receptor (GLP-1R), a class B G protein-coupled receptor. Cryo-EM structures show semaglutide engages the GLP-1R similarly to native GLP-1 but with distinct receptor dynamics. Proposed mechanisms include: (1) reducing appetite and increasing satiety, decreasing dietary intake and free fatty acid export to the liver; (2) reducing insulin resistance and improving insulin sensitivity; (3) reducing de novo lipogenesis by downregulating ChREBP and SREBP-1c signaling; (4) reducing weight of white and brown adipose tissue; (5) reducing inflammation by decreasing pro-inflammatory markers in GLP-1-expressing macrophages and favorably altering gut microbiota. In the cardiovascular context, semaglutide restores RKIP expression and inhibits the downstream TBK1-NF-κB pathway through Sirt3-dependent signaling, with cAMP/PKA signaling contributing to the anti-inflammatory effect. In adipose and vascular tissue, semaglutide modulates the GLP-1R/PPARG/ACSL1 pathway in macrophages and increases antithrombotic gelsolin secretion from epicardial fat (PMID 39908200, PMID 38172989). The lack of confirmed GLP-1 receptor expression in human and mouse liver suggests liver-related benefits are likely indirect.

Class: Glucagon-like peptide-1 receptor agonist (GLP-1 RA)

Administration & storage

Administration
Subcutaneous injectiononce weekly (PMID: 33667417PMID: 35131037PMID: 34293304PMID: 42456707)Oral administrationonce daily (PMID: 39082206PMID: 38808476PMID: 41765029PMID: 33184979)Subcutaneous injection via pre-filled pen (PMID: 40849680)
Storage
No storage conditions for semaglutide are explicitly stated in the reviewed abstracts. Storage guidance requires manual verification from prescribing information.
Cautions
Compounded semaglutide products may lack quality controls of approved formulations, raising risks of dosing errors and adverse outcomes; fraudulent products have been identified globally.,Semaglutide administered via pre-filled pen is dose-limited per injection; self-injection of multiple doses (e.g., a full monthly supply at once) can result in serious overdose with multiorgan failure, hypoglycemia, and GI complications.,Oral semaglutide bioavailability is highly sensitive to water volume and fasting duration; deviating from recommended dosing conditions (≤120 mL water, 30-min post-dose fast) significantly alters drug exposure.,Higher doses associated with greater muscle mass loss in older adults with T2D, particularly in patients with pre-existing sarcopenia.,Sterile technique should be used for all subcutaneous injections to prevent contamination and infection at the injection site.,Patients with pre-existing diabetic retinopathy, especially those ≥60 years or with diabetes duration ≥10 years, should be carefully monitored for retinopathy worsening during semaglutide treatment (PMID: 34894326, PMID: 34305810).

Legal & regulatory status

US FDA

FDA approved under brand name Ozempic for treatment of type 2 diabetes and Wegovy for treatment of overweight or obesity; oral semaglutide (Rybelsus) approved for type 2 diabetes. Compounded versions exist both legally…

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification